Associated Papers
Malignant adenomyoepithelioma with HRAS G13R mutation: A case report.
Kuwabara H et al.
Oncology Letters, 2026
Characterizing Paratesticular Neoplasms in Proteus Syndrome.
Matoso A et al.
The American Journal of Surgical Pathology, 2026
Genetic analysis of key players in PI3K signaling cascade of colorectal carcinoma.
Pervaiz H et al.
Scientific Reports, 2026
Circulating cell-free DNA profiling reveals ancestry-dependent genetic variation in metastatic prostate cancer.
Maleknia S et al.
Molecular Biomedicine, 2026
The prognostic impact of CDKN2A/B hemizygous deletions in meningioma.
Ippen FM et al.
Neuro-oncology, 2026
Using the Reactome Graph Database to generate pathway fingerprints for cancer-related genes, and using the fingerprints to gain insights into cancer, comorbidity, and cancer gene networks.
Iengar P et al.
Computational Biology and Chemistry, 2026
Decoding non-coding SNPs: systems genomics modelling dissects the heterogeneity of IBD.
Módos D et al.
Molecular Systems Biology, 2026
Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.
Saito Y et al.
Nature Medicine, 2026
Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer.
Ochman B et al.
International Journal of Molecular Sciences, 2026
Distinct genomic, microenvironmental, and nephron signatures in VHL kidney cysts and tumors.
Rowe I et al.
Scientific Reports, 2026
Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion.
Zaghla BKQ et al.
Journal for Immunotherapy of Cancer, 2026
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.
Juric D et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.
Lloyd MR et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer.
Wang Y et al.
Military Medical Research, 2026
Decoding the Mutational Hierarchy of Thyroid Cancer and Associated Signaling Pathways.
Nashier D et al.
Archives of Medical Research, 2026
Prenatal Diagnosis of Malformations of Cortical Development: A Review of Genetic and Imaging Advances.
Hu J et al.
Biomedicines, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Rose AAN et al.
Nature Communications, 2026
From PIK3CA Mutations to Rational PI3K Inhibition for the Treatment of Colorectal Cancer.
Voutsadakis IA
Molecular Diagnosis & Therapy, 2026
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Phylogenetic analysis of paired breast carcinomas identifies genetic events associated with clonal recurrence and invasive progression.
Kader T et al.
The Journal of Pathology, 2026
The structural heterogeneity of AKT autoinhibition.
Xu L et al.
Protein Science : a Publication of the Protein Society, 2026
Mutation in IR or IGF1R produces features of long-lived mice while maintaining metabolic health.
Hernández-Arciga U et al.
Jci Insight, 2025
Mutant CHCHD10 disrupts cytochrome c oxidation and activates mitochondrial retrograde signaling.
Campos-Ribeiro MA et al.
Embo Molecular Medicine, 2025
Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer.
Alves CL et al.
Science Translational Medicine, 2025
Non-redundant roles of the phosphoinositide phosphatases PTEN and PIPP in PI3K/AKT signaling in breast cancer.
Ooms LM et al.
Communications Biology, 2025
Widespread Epistasis between Cancer Driver Mutations and Allele-Specific Copy Number Variations.
Merzliakov S et al.
Biorxiv : the Preprint Server for Biology, 2025
Phosphoproteomics unveils the signaling dynamics in neuronal cells stimulated with insulin and insulin-like growth factors.
Ushakumary MG et al.
Cell Communication and Signaling : Ccs, 2025
Assessing endocrine resistance: monitoring circulating ESR1 mutations in Irosustat-treated ER positive breast cancer.
Page K et al.
Breast Cancer Research and Treatment, 2025
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
Glial cells are involved in day-night protein dysregulation in the hippocampus of a mouse model of Alzheimer's disease.
Badina AM et al.
Scientific Reports, 2025
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K.
McCourt CK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Deciphering genetic susceptibility to clear cell renal cell carcinoma.
Mandelia M et al.
Communications Biology, 2025
Rare recurrent multiple pulmonary sclerosing pneumocytoma with sarcomatoid features: A case report and literature review.
Jiang N et al.
Journal of Cancer Research and Therapeutics, 2025
Structural insights of AKT and its activation mechanism for drug development.
Kumar BH et al.
Molecular Diversity, 2025
Analytical Validation of a Pan-Cancer Next-Generation Sequencing Assay for In-House Liquid Biopsy Testing: An International Multicenter Study.
Lescuyer G et al.
The Journal of Molecular Diagnostics : Jmd, 2025
Deciphering the Impact of AKT1 Pathogenic Variants in Juvenile Granulosa Cell Tumors Using a Drosophila Model.
Veitia RA et al.
Molecular & Cellular Proteomics : Mcp, 2025
WEE1 inhibitors trigger GCN2-mediated activation of the integrated stress response.
Tjeerdsma RB et al.
Nature Communications, 2025
Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients.
Smolenschi C et al.
Npj Precision Oncology, 2025
Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts.
Òdena A et al.
Npj Precision Oncology, 2025
Genetic drivers of Chinese hamster ovary cell proliferation revealed by functional genomics.
Marzluf J et al.
Iscience, 2025
Translating genomic insights into therapy: an NGS-based mutation profiling study in breast cancer.
Bhavnagari HM et al.
Medical Oncology (northwood, London, England), 2025